Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18839612 | 0.83 | MAPKAPK2 (0.41) | ATRALDH1A1MAPTMAPKAPK2RORC | |
| SCHEMBL17986656 | 0.82 | MAPT (0.37) | MAPTNPSR1MAPKAPK2SMN1; SMN2KMT2A | |
| SCHEMBL18805715 | 0.81 | RORC (0.53) | ATRMAPKAPK2SYKRORC | |
| SCHEMBL18862940 | 0.80 | MALT1 (0.40) | ATRALDH1A1MAPTMAPKAPK2RORC | |
| SCHEMBL5593053 | 0.80 | ALDH1A1 (0.47) | ALDH1A1MAPTNPSR1NPC1MAPKAPK2 | |
| SCHEMBL17986785 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MAPTNPSR1NPC1TP53 | |
| SCHEMBL1010435 | 0.79 | ATR (0.46) | ATRALDH1A1MAPKAPK2RORC | |
| SCHEMBL23608711 | 0.78 | RORC (0.41) | ATRMAPKAPK2RORC | |
| SCHEMBL29882694 | 0.78 | RORC (0.41) | ATRMAPKAPK2RORC | |
| SCHEMBL5863937 | 0.77 | MAPKAPK2 (0.39) | ALDH1A1MAPTNPSR1MAPKAPK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473499-B | Novel pyrazolopyrimidine derivatives | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | NOVARTIS PHARMA AG (CH) | 2020-09-17 | — | — | US | disclosed |
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | NOVARTIS PHARMA AG (CH) | 2020-09-17 | — | — | US | disclosed |
| EP-3374361-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017081641-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017081641-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2017-05-18 | — | — | WO | disclosed |
| WO-2006112828-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20050288299-A1 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS INC. | 2005-12-29 | — | — | US | disclosed |
| US-6890934-B2 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6573274-B1 | Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1136492-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | PDE2A, PDE3A, PDE5A | ATR 2719/4885ALDH1A1 476/4885MAPT 4144/4885 |
| US-20200289514-A1 | Novel Pyrazolo Pyrimidine Derivatives | MMEL1, PPME1, CTSC | ATR 2574/4885ALDH1A1 3274/4885MAPT 3426/4885 |
| US-20050288299-A1 | Azaindole derivatives as inhibitors of p38 kinase | MAPKAPK2, MAPK1, MAPK3 | ATR 1319/4885ALDH1A1 1498/4885MAPT 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.